ANPEP and glioma: Since a higher CD13 level in the glioma (WHO grade III-IV) was detected than that in the gliom (I-II) using immunohistochemistry in our preliminary study (data not shown), we assumed that the MSN-DOX-PDA-NGR exhibited more powerful antitumor effects against the high-grade glioma than against low-grade.